The Company

To date, there are no approved drugs for the prevention or treatment of any sensorineural hearing loss disorder or tinnitus. AudioCure Pharma is determined to change this.

AudioCure Pharma GmbH is a pharmaceutical company with a focus on hearing impairments. Operational since 2012, AudioCure was founded by Professor Hans Rommelspacher; a clinician and academic who has dedicated his career to the discovery and preclinical development of drug candidates. He is joined by highly skilled scientists and executives as well as a tight-knit network of academic partners, internationally renowned advisors and strategic investors.

Taking a comprehensive approach to hearing loss

AudioCure is based in Berlin, Germany. Our office is located in a peaceful courtyard in the central area of Mitte. As such, we benefit from being within easy reach of the main train station and many other Berlin high-tech companies and universities while also enjoying the hustle and bustle of this vibrant capital city. We have close ties to the Charité University which allows for a close interaction with the experts of this world renowned institution. Our front-runner compound AC102 is currently being evaluated in a Phase II clinical trial for the treatment of idiopathic sudden sensorineural hearing loss. The Phase I study in healthy volunteers has been successfully completed in 2021.